<DOC>
	<DOCNO>NCT01618162</DOCNO>
	<brief_summary>This trial conduct Asia , Europe United States America ( USA ) . The aim trial investigate efficacy safety insulin degludec/liraglutide insulin na√Øve subject inadequately control SU ( sulphonylurea ) alone combination metformin . All subject continue pre-trial SU treatment without metformin treatment without change frequency dose throughout trial .</brief_summary>
	<brief_title>The Efficacy Insulin Degludec/Liraglutide add-on Therapy Controlling Glycaemia Adults With Type 2 Diabetes Inadequately Controlled Sulphonylurea With Without Metformin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects type 2 diabetes mellitus HbA1c 7.09.0 % ( 5375 mmol/mol ) ( inclusive ) Subjects stable daily dose sulphonylurea ( equal half max approve dose accord local label ) without metformin ( equal 1500 mg max tolerate dose ) least 90 day prior screen visit ( Visit 1 ) Body Mass Index ( BMI ) equal 40 kg/m^2 Any use oral antidiabetic drug ( OADs ) ( SU monotherapy combinationwith metformin ) equal 90 day prior screen visit ( Visit 1 ) Use drug ( SU monotherapy combination metformin ) , Investigators opinion could interfere blood glucose level ( e.g . systemic corticosteroid ) Previous treatment glucagonlike peptide1 ( GLP1 ) receptor agonist ( e.g . exenatide , liraglutide ) Treatment insulin regimen ( short term treatment due intercurrent illness include gestational diabetes allow discretion Investigator ) Screening calcitonin equal 50 ng/l Personal family history medullary thyroid carcinoma ( MTC ) multiple endocrine neoplasia type 2 ( MEN2 ) Cardiovascular disorder define : congestive heart failure ( New York Heart Association ( NYHA ) class IIIIV ) , diagnosis unstable angina pectoris , cerebral stroke and/or myocardial infarction within past 52 week prior screen visit ( Visit 1 ) and/or plan coronary , carotid peripheral artery revascularisation procedure Proliferative retinopathy require acute treatment maculopathy ( macular oedema ) accord Investigator 's opinion Subjects clinical significant , active ( past 12 month ) disease gastrointestinal , pulmonary , endocrinological ( except Type 2 Diabetes Mellitus ) , neurological , genitourinary haematological system opinion Investigator , may confound result trial pose additional risk administer trial product History chronic pancreatitis idiopathic acute pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>